TG6-10-1 (C007B-431030)

TG6-10-1 is an EP2 antagonist, shows low-nanomolar antagonist activity against only EP2, >300-fold selectivity over human EP3, EP4, and IP receptors, 100-fold selectivity over EP1 receptorsIn VitroTG6-10-1 robustly blocks prostaglandin E2 (PGE2) (10 μM)-induced cAMP accumulation in a concentration-dependent manner in SH-SY5Y cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoTG6-10-1 (5 mg/kg; i.p.; 4-30 hours) improves survival, accelerates recovery of lost weight, and improves functional recovery following status epilepticus (SE) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6 mice (pilocarpine-induced SE) Dosage: 5 mg/kg Administration: Intraperitoneal injection; 4, 21, 30 hours Result: A significant increase in survival and accelerating the recovery of lost weight in post-SE mice.Form:SolidIC50& Target:EP2.

Specifications and Purity: ≥99%

Molecular Formula: C23H23F3N2O4

Molecular Weight: 448.4

PubChem CID: 71499384

Isomeric SMILES: COC1=CC(=CC(=C1OC)OC)/C=C/C(=O)NCCN2C3=CC=CC=C3C=C2C(F)(F)F